このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Phase I Dose-Escalation Study of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors

2026年11月12日 更新者:Cugene Inc.

A Phase I, First-In-Human, Open-Label, Multicenter, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors

CUG279-P101 is a first-in-human, open-label, multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, immune-pharmacodynamics, and preliminary antitumor activity of CUG279 in adults with select unresectable advanced or metastatic solid tumors.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

The study will consist of two parts: Part A Dose Escalation and Part B Dose Expansion

研究の種類

介入

入学 (推定)

65

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Admin Cugene
  • 電話番号:1(781) 893-5800
  • メール:admin@cugene.com

研究場所

    • Virginia
      • Fairfax、Virginia、アメリカ、22031
        • 募集
        • NEXT Virginia

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Signed and dated informed consent.
  2. Histologically or cytologically confirmed selected locally advanced or metastatic solid tumor.
  3. At least 1 measurable lesion according to RECIST v1.1.
  4. Progressed after, intolerant to, declined, or not considered a candidate for available standard-of-care (SoC) therapy.
  5. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
  6. Adequate cardiovascular, hematologic, renal, hepatic, and coagulation function.
  7. Life expectancy of ≥3 months.
  8. Female participants must not be pregnant or breastfeeding. Male participants with female partners of childbearing potential must agree to use effective contraception as specified in the protocol.

Exclusion Criteria

  1. Rapidly progressing disease or disease requiring urgent alternative medical intervention.
  2. Recent or concurrent malignancy, except certain adequately treated or low-risk malignancies as specified in the protocol.
  3. Prior anticancer, investigational, radiation, or immunomodulatory therapy within protocol-specified washout periods, or prior IL-2/IL-15-based therapy.
  4. Concurrent participation in another interventional therapeutic clinical trial.
  5. Active or clinically significant CNS disease, including symptomatic CNS metastases or leptomeningeal disease, except as specified in the protocol.
  6. Clinically significant autoimmune disease, immunodeficiency, requirement for systemic immunosuppressive therapy, or history of severe immune-mediated adverse events.
  7. Unresolved clinically significant toxicities from prior anticancer therapy.
  8. Clinically significant cardiovascular, thromboembolic, pulmonary, hepatic, or gastrointestinal disease.
  9. Active or clinically significant infection except as specified in the protocol.
  10. Recent major surgery or trauma, or prior allogeneic hematopoietic stem cell, bone marrow, or solid organ transplantation.
  11. Known hypersensitivity or significant allergic reaction to biologics or its components.
  12. Recent vaccination, except as permitted by the protocol.
  13. Any medical, psychological, social, or other condition that, in the Investigator's opinion, may increase risk, interfere with study participation, or confound interpretation of study results

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:順次割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Part A Dose Escalation

CUG279 will be administered at multiple ascending dose levels

CUG279 will be administered intravenously according to the protocol

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of dose limiting toxicities (DLTs)
時間枠:From the first dose up to 21 days post-dose

The number and percentage of participants with DLTs will be assessed according to the protocol-specified DLT criteria in Part A.

From the first dose up to 21 days post-dose
Incidence and severity of treatment-emergent adverse events (TEAEs)
時間枠:From first dose through 90 days after the last dose

The number and percentage of participants with TEAEs will be assessed. AEs will be graded according to NCI-CTCAE Version 6.0.

From first dose through 90 days after the last dose
Incidence of serious adverse events (SAEs)
時間枠:From first dose through 90 days after the last dose

The number and percentage of participants with SAEs will be assessed.

From first dose through 90 days after the last dose
Clinically significant changes in safety laboratory parameters from baseline
時間枠:From first dose through 90 days after the last dose

Clinically significant changes from baseline in safety laboratory parameters will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0

From first dose through 90 days after the last dose
Clinically significant changes in electrocardiogram (ECG) findings from baseline
時間枠:From first dose through 90 days after the last dose

Clinically significant changes from baseline in ECGs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0

From first dose through 90 days after the last dose
Clinically significant changes in vital signs from baseline
時間枠:From first dose through 90 days after the last dose

Clinically significant changes from baseline in vital signs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0.

From first dose through 90 days after the last dose
Incidence of TEAEs leading to dose modifications
時間枠:From the first dose through the last dose; up to 1 year

The number and percentage of participants with TEAEs leading to CUG279 dose modification will be assessed.

From the first dose through the last dose; up to 1 year

二次結果の測定

結果測定
メジャーの説明
時間枠
Maximum observed plasma concentration (Cmax) of CUG279
時間枠:From first dose through 90 days after the last dose

The maximum observed plasma concentration (Cmax) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Trough plasma concentrations (Ctrough) of CUG279
時間枠:From first dose through 90 days after the last dose

The trough plasma concentration (Ctrough) of CUG279 will be determined from plasma samples collected immediately before the next scheduled dose

From first dose through 90 days after the last dose
Area under the concentration-time curve (AUC) of CUG279
時間枠:From first dose through 90 days after the last dose

The area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-last) of CUG279 will be calculated using plasma concentration-time data.

From first dose through 90 days after the last dose
Terminal half-life (T1/2) of CUG279
時間枠:From first dose through 90 days after the last dose

The terminal elimination half-life (t½) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Systemic clearance (CL) of CUG279
時間枠:From first dose through 90 days after the last dose

The systemic clearance (CL) of CUG279 will be determined from plasma concentration-time data

From first dose through 90 days after the last dose
Volume of distribution (Vz) of CUG279
時間枠:From first dose through 90 days after the last dose

The volume of distribution (Vz) of CUG279 will be determined from plasma concentration-time data.

From first dose through 90 days after the last dose
Incidence of anti-CUG279 antibodies (ADA)
時間枠:From first dose through 90 days after the last dose

Number and percentage of participants with treatment-emergent or treatment-enhanced anti-CUG279 antibodies will be determined.

From first dose through 90 days after the last dose
Incidence of anti-CUG279 neutralizing antibodies (NAb)
時間枠:From first dose through 90 days after the last dose

Number and percentage of participants with neutralizing anti-CUG279 antibodies will be determined

From first dose through 90 days after the last dose
Objective response rate (ORR)
時間枠:From the first dose through study completion or until disease progression; up to 1 year

Percentage of participants whose best overall response is a confirmed complete response (CR) or partial response (PR) will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Disease control rate (DCR)
時間枠:From the first dose through study completion or until disease progression; up to 1 year

Percentage of participants whose best overall response is CR, PR, or stable disease (SD) will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Time to response (TTR)
時間枠:From the first dose through study completion or until disease progression; up to 1 year

Time from the first dose of CUG279 to the first documented CR or PR will be determined, per RECIST v1.1

From the first dose through study completion or until disease progression; up to 1 year
Duration of response (DoR)
時間枠:From the first dose through study completion or until disease progression; up to 1 year

Time from first documented CR or PR to disease progression will be determined per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Best overall response (BOR)
時間枠:From the first dose through study completion or until disease progression; up to 1 year

Best confirmed overall tumor response recorded from the first dose until disease progression or the end of efficacy assessment will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year
Progression-free survival (PFS)
時間枠:From the first dose through study completion or until disease progression; up to 1 year

Time from the first dose of CUG279 to radiographic disease progression will be determined, per RECIST v1.1.

From the first dose through study completion or until disease progression; up to 1 year

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年11月5日

一次修了 (推定)

2029年3月30日

研究の完了 (推定)

2029年3月30日

試験登録日

最初に提出

2026年10月19日

QC基準を満たした最初の提出物

2026年11月12日

最初の投稿 (実際)

2026年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • CUG279-P101
  • IND 179862 (U.S. FDA IND) (その他の識別子:FDA)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。